|
|
Article: United States Awards Patent to Antigen Express Subsidiary of Generex Biotechnology; Divisional Award in Ii-Key Hybrids Technology to Inhibit Antigen Presentation to Immunoregulatory T cells.
- Article from:
- PR Newswire
- Article date:
- January 27, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Generex Biotechnology Corporation announced today that its wholly owned subsidiary, Antigen Express, has received United States Patent US 6,835,382 B2 as of December 28, 2004. This award continues the divisional prosecution of an original application filed March 3, 1999. The specific award covers the use of Ii-Key peptide homologs to inhibit antigen presentation. It bears on potential treatments of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and diabetes mellitus.
Dr. Robert Humphreys, the Chief Scientific Officer of Antigen Express has spent his lifetime understanding how antigenic peptides are presented to the immune system and how ...